Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

BACKGROUND: Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine), oxaliplatin and/or irinotecan, combined with either anti-VEGF (bevacizumab) or, for R...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommerhäuser, G., Kurreck, A., Stintzing, S., Heinemann, V., von Weikersthal, L. Fischer, Dechow, T., Kaiser, F., Karthaus, M., Schwaner, I., Fuchs, M., König, A., Roderburg, C., Hoyer, I., Quante, M., Kiani, A., Fruehauf, S., Müller, L., Reinacher-Schick, A., Ettrich, T. J., Stahler, A., Modest, D. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327141/
https://www.ncbi.nlm.nih.gov/pubmed/35897060
http://dx.doi.org/10.1186/s12885-022-09892-8

Ejemplares similares

Ejemplares similares